Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Trigger Finger Disorder 1Stomach Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Nose Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Kidney Neoplasms 1Ganglion Cysts 1Esthesioneuroblastoma, Olfactory 1Dupuytren Contracture 1De Quervain Disease 1Colorectal Neoplasms 1Cognitive Dysfunction 1Carpal Tunnel Syndrome 1Cachexia 1Biliary Tract Neoplasms 1

Interventions

Memantine 2lithium sulfate 1lime 1fasudil 1XENP 1595 1Ramipril 1Methylphenidate 1Lithium 1Infliximab 1Ibuprofen 1Exercise 1Cannabidiol 1Behavior Therapy 1Aspirin 1Ashwagandha 1Anticonvulsants 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cognitive Dysfunction × Ibuprofen × Clear all
NCT03186638 2023-09-25

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

University of Rochester

Phase 2 Completed
87 enrolled 13 charts

Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡